In the last few years, several clinical trials have demonstrated the efficacy of cetuximab, a chimeric IgG1 monoclonal antibody that binds to the epidermal growth factor receptor, in the treatment of metastatic colorectal cancer.1,2 The most frequent cutaneous adverse effect of cetuximab therapy is an acneiform eruption, observed in approximately 90% of patients within 1 to 3 weeks after therapy initiation.1- 5
Micantonio T, Fargnoli MC, Ricevuto E, Ficorella C, Marchetti P, Peris K. Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy. Arch Dermatol. 2005;141(9):1173–1174. doi:10.1001/archderm.141.9.1173
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.